This article is more than 5 years old. Information may no longer be current.
MADIT-II: Risk of long-term mortality reduced with ICDs
Patients implanted with ICDs fared better than those who were not in an eight-year follow-up of the trial.
Click Here to Manage Email Alerts
Heart Rhythm Society's 30th Annual Scientific Sessions
Results of the MADIT-II trial showed that patients who received an implantable cardioverter defibrillator had a 45% mortality probability compared with a 61% risk among patients who did not receive the device.
Results from an eight-year follow-up of the MADIT-II randomized trial, which included 1,232 post-MI patients with an ejection fraction ≥30% and NYHA 1-III, demonstrated that device efficacy was better among patients with limited right ventricular pacing and those who did not further progress in HF. The patients had ischemic left ventricular dysfunction. Follow-up was conducted through November 2001. Previously, the researchers demonstrated short-term benefit in the MADIT-II cohort receiving ICDs at 20 months follow-up (P=0.016). The researchers utilized post-trial mortality data from the United States (through December 2006) and European (through March 2009) National Death Registries to help them come to the conclusions they presented today at Heart Rhythm 2009, according to the abstract.
“We have shown that the ICD has sustained efficacy saving lives, providing incremental survival benefit to a follow-up period of at least eight years,” Ilan Goldenberg, MD,of the heart research follow-up program at the University of Rochester Medical Center in Rochester, N.Y., said during his presentation.
The 16% increase in mortality risk among patients who do not receive an ICD translates to 1.2 life-years saved with an ICD during the eight-year time period, Goldenberg said. – by Judith Rusk
For more information:
- Goldenberg I. LBCT I. Presented at: Heart Rhythm 2009; May 13-16, 2009; Boston.
More HRS meeting highlights >>